Jiangsu Hillgene is a cell and gene therapy drug CDMO company with core technologies for industrialization. The company as a whole is conducted independently after the spin-off of the CDMO business of Shenzhen Pregene Bio-pharmaceutical Co., Ltd.
The company's shareholders comprise the China SME Development Fund, CAS Holdings Guokejiahe Fund, Haier Medical, Huapont Life Science, Hunan Health and Pension Fund, etc. The company is headquartered in the gorgeous shore of Taihu Lake-Wuzhong District, Suzhou City, with a registered capital of 100 million RMB.
The company possesses Suzhou headquarters (7000 m2 GMP plant), Zhengzhou base (7000 m2 GMP plant under construction), Changchun base (cooperation with the First Bethune Hospital of Jilin University, 5000 m2 GMP plant under construction), and has initially developed a national layout of the production base network layout.